ATRICURE INC

Insight into AtriCure’s insider sales shows CSO Vinayak’s 6,000‑share move is a tactical liquidity pull‑back, not a warning, as the company’s stock hits a 52‑week high.

Insider sale at AtriCure: Karen Prange sells 3,000 shares, showing routine portfolio rebalancing and confidence in the company’s medical‑device pipeline.

Insight into AtriCure’s mid‑May insider sale: CSO’s 5,000 shares sold near market highs show routine liquidity, not a bearish warning.

Insider buying spurs confidence in AtriCure (ATR) after 13% revenue lift and strong Q4 earnings, highlighting executives’ long‑term commitment.